Singular technology to identify, characterize, and advance therapeutic antibodies.
Today’s discovery technologies produce antibody drugs from ‘fully human’ or ‘humanized’ transgenic animals or microbial systems. These approaches lack the context of the human proteome, specific selection against human immunogenicity, and the diversity of human antibody genetics that provide effective drugs.
Many antibody-based drugs fail at the efficacy stage. Human immune systems produce effective drugs against native, in vivo targets which can’t be replicated outside the human body.
Human-derived antibodies are less likely to trigger immune reactions when given to patients because the immune system recognizes them as ‘self’. This reduces the risk of adverse reactions and improves safety and efficacy, by minimizing damage to healthy cells and tissues.
Human-derived antibodies are less likely to trigger immune reactions when given to patients because they are recognized as ‘self’ by our immune system. This reduces the risk of adverse reactions and brings improved safety and efficacy.
Human-derived antibodies are more likely to exhibit high binding specificity to their target antigens, which enhances their therapeutic effectiveness. This maximizes therapeutic benefit and minimizes off-target effects.
Human-derived antibodies have the potential for better pharmacokinetic profiles, longer half-life, and enhanced tissue distribution. This can improve dosing schedules and improve the patient experience.
Human-derived antibodies arise in a complex biological system that model organisms do not recapitulate. Infinimmune is filling its pipeline with first- and best-in-class drugs identified by the human immune system against known and novel targets.